Sonic Incytes Medical Corp. Successfully Completes Series A Raise of US$7.3M to Accelerate Velacur™ Commercialization VANCOUVER, British Columbia, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corp., a health technology company focused on liver health, is pleased to announce the completion of its US$7.3M...

Velacur™ Data Presented at 2021 AASLD The Liver Meeting® VANCOUVER, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corp. is pleased to announce that data from its sponsored clinical study of VelacurTM – the first handheld 3D liver health...

Sonic Incytes Showcases Velacur™ at ACG 2021 VANCOUVER, British Columbia, Oct. 13, 2021 (GLOBE NEWSWIRE) -- In recognition of Liver Awareness Month this October, Sonic Incytes Medical Corp. is pleased to showcase VelacurTM, the first handheld...

Sonic Incytes Announces FDA Clearance and US Launch of Velacur™ to Help Manage Emerging Health Crisis VANCOUVER, British Columbia, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corporation is pleased to announce the US commercial release of VelacurTM, the world’s first handheld 3D liver...